Found 86 results
[ Author(Asc)] Title Type Year
Filters: Author is Luiz E Bermudez  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Chee, C. B., Aralar, P., Petrofsky, M., Parman, T., Green, C. E., Lewin, A. H., Ellis, W. Y., and Young, L. S., Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine against Mycobacterium avium Infection in Mice., Antimicrobial agents and chemotherapy, vol. 56, no. 8, pp. 4202-6, 2012.
L. E. Bermudez, Petrofsky, M., Sommer, S., and Barletta, R. G., Peyer's patch-deficient mice demonstrate that Mycobacterium avium subsp. paratuberculosis translocates across the mucosal barrier via both M cells and enterocytes but has inefficient dissemination., Infection and immunity, vol. 78, no. 8, pp. 3570-7, 2010.
L. E. Bermudez, Motamedi, N., Kolonoski, P., Chee, C., Baimukanova, G., Bildfell, R. J., Wang, G., Phan, L. Tam, and S Lowell, Y., The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection., The Journal of infectious diseases, vol. 197, no. 11, pp. 1506-10, 2008.
L. E. Bermudez, Motamedi, N., Chee, C., Baimukanova, G., Kolonoski, P., Inderlied, C., Aralar, P., Wang, G., Phan, L. Tam, and Young, L. S., EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium., Antimicrobial agents and chemotherapy, vol. 51, no. 5, pp. 1666-70, 2007.
L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S., SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease., Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.
L. E. Bermudez and Yamazaki, Y., Effects of macrolides and ketolides on mycobacterial infections., Current pharmaceutical design, vol. 10, no. 26, pp. 3221-8, 2004.
L. E. Bermudez, Petrofsky, M., and Sangari, F., Intracellular phenotype of Mycobacterium avium enters macrophages primarily by a macropinocytosis-like mechanism and survives in a compartment that differs from that with extracellular phenotype., Cell biology international, vol. 28, no. 5, pp. 411-9, 2004.
L. E. Bermudez, Kolonoski, P., Petrofsky, M., Wu, M., Inderlied, C. B., and Young, L. S., Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease., The Journal of infectious diseases, vol. 187, no. 12, pp. 1977-80, 2003.
L. E. Bermudez, Reynolds, R., Kolonoski, P., Aralar, P., Inderlied, C. B., and Young, L. S., Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice., Antimicrobial agents and chemotherapy, vol. 47, no. 8, pp. 2685-7, 2003.
L. E. Bermudez, Sangari, F. J., Kolonoski, P., Petrofsky, M., and Goodman, J., The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells., Infection and immunity, vol. 70, no. 1, pp. 140-6, 2002.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S., Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium., Antimicrobial agents and chemotherapy, vol. 45, no. 1, pp. 217-22, 2001.
L. E. Bermudez and Sangari, F. J., Cellular and molecular mechanisms of internalization of mycobacteria by host cells., Microbes and infection / Institut Pasteur, vol. 3, no. 1, pp. 37-42, 2001.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Aralar, P., and Young, L. S., Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment., Antimicrobial agents and chemotherapy, vol. 45, no. 8, pp. 2210-4, 2001.
L. E. Bermudez, Nash, K., Petrofsky, M., Young, L. S., and Inderlied, C. B., Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice., Antimicrobial agents and chemotherapy, vol. 44, no. 10, pp. 2619-22, 2000.
L. E. Bermudez, Wagner, D., and Sosnowska, D., Mechanisms of Mycobacterium avium pathogenesis., Archivum immunologiae et therapiae experimentalis, vol. 48, no. 6, pp. 521-7, 2000.
L. E. Bermudez and Sangari, F. J., Mycobacterial invasion of epithelial cells., Sub-cellular biochemistry, vol. 33, pp. 231-49, 2000.
L. E. Bermudez, Wu, M., Miltner, E., and Inderlied, C. B., Isolation of two subpopulations of Mycobacterium avium within human macrophages., FEMS microbiology letters, vol. 178, no. 1, pp. 19-26, 1999.
L. E. Bermudez, Goodman, J., and Petrofsky, M., Role of complement receptors in uptake of Mycobacterium avium by macrophages in vivo: evidence from studies using CD18-deficient mice., Infection and immunity, vol. 67, no. 9, pp. 4912-6, 1999.
L. E. Bermudez and Petrofsky, M., Host defense against Mycobacterium avium does not have an absolute requirement for major histocompatibility complex class I-restricted T cells., Infection and immunity, vol. 67, no. 6, pp. 3108-11, 1999.
L. E. Bermudez, Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B., and Young, L. S., Mefloquine is active in vitro and in vivo against Mycobacterium avium complex., Antimicrobial agents and chemotherapy, vol. 43, no. 8, pp. 1870-4, 1999.
L. E. Bermudez, Parker, A., and Petrofsky, M., Apoptosis of Mycobacterium avium-infected macrophages is mediated by both tumour necrosis factor (TNF) and Fas, and involves the activation of caspases., Clinical and experimental immunology, vol. 116, no. 1, pp. 94-9, 1999.
L. E. Bermudez, Sangari, F. J., and Parker, A., Green fluorescent protein in the measurement of bacteria-host interactions., Methods in enzymology, vol. 302, pp. 285-95, 1999.
L. E. Bermudez, Petrofsky, M., Wu, M., and Young, L. S., Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice., The Journal of infectious diseases, vol. 178, no. 3, pp. 896-9, 1998.
L. E. Bermudez, Petrofsky, M., and Stevens, P., Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice., Immunology, vol. 94, no. 3, pp. 297-303, 1998.
L. E. Bermudez, Petrofsky, M., Kolonoski, P., and Young, L. S., Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy., Antimicrobial agents and chemotherapy, vol. 42, no. 1, pp. 180-3, 1998.

Pages